MedTrace Logo

China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)

NCT05221580 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 887

Last updated 2024-06-14

No results posted yet for this study

Summary

The purpose of this study is to collect information on how Ryzodeg® works in real-world patients.

Participants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Ryzodeg®

Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-18
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05221580 on ClinicalTrials.gov